StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Geojit Financial Services

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byGeojit Financial ServicesHorizon: NA (inferred 1 year)3 Sept 2025via Institutional / Brokerage Research

Entry₹1,008.2Inferred
Target₹1,121
Total upside +11.19% (call closed)
Stop lossNot given
Exit₹1,12123 Jun 2026, 12:06 pm
Target hit+11.19%0.00%upside left
Follow Geojit Financial Services for new calls(74% target hit, 423 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 7 active Long-term calls on ZYDUSLIFESee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:52 pm IST
10 supporting4 neutral2 opposing
Supports the BUY call (10)

Zydus Lifesciences Limited announces the completion of the merger of its subsidiary Zara Merger Sub Inc. with Assertio Holdings Inc. Assertio has now become a wholly owned subsidiary of Zydus Lifescie

BSE · Company Update·16 Jun · 6d ago

(opens in new tab)

Zydus Lifesciences Ltd announced the successful completion of its acquisition of Assertio Holdings.

BSE · Company Update·16 Jun · 6d ago

(opens in new tab)

Zydus Lifesciences Limited's New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) has been granted Priority Review by the US FDA.

NSE · Press Release·28 May · 4w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·25 Aug · 10mo ago

Neutral / worth noting (4)

Zydus Lifesciences Limited has extinguished 87,30,158 equity shares as part of its buyback program. This action reduces the total number of outstanding shares.

BSE · Company Update·19 Jun · 3d ago

(opens in new tab)

Zydus Lifesciences Ltd has issued an addendum to its public announcement regarding the buyback of equity shares.

BSE · Company Update·27 May · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Geojit Financial Services

Every call and its outcome